Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM: Linvoseltamab in Post-BCMA CAR T-Cell Therapy Relapse Multiple Myeloma
NCT07009899Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linvoseltamab in multiple myeloma (MM), sponsored by Medical College of Wisconsin. Primary endpoint: Overall Response Rate at 15 months. Started Aug 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07009899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009899.